DPP-4 Inhibitors :: Diabetes Self-Management
Links shared publicly online about this topic.
- 1,828total visits
DPP-4 Inhibitors :: Diabetes Self-Management
View full resource at diabetesselfmanagement.com
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Drug, Onglyza, Januvia
Most Recently Shared on August 12, 2009 at 7:05 pm By:
#diabetes Article of the Week: DPP-4 Inhibitors: A Novel Class of Drugs for Type 2 Diabetes http://bit.ly/19Q8o8
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
clinical.diabetesjournals.org — “Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence” View full resource at clinical.diabetesjournals.org
Most Recently Shared on February 4, 2012 at 4:21 am By:
Yvo Sijpkens MD Doctor, Internist, Nephrologist, and Physician
How to select among GLP-1 receptor agonists and DPP-4 inhibitors? #diabetes http://t.co/4PpobaSG
Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes
news-medical.net — “Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.” View full resource at news-medical.net
Most Recently Shared on January 31, 2012 at 12:29 pm By:
Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes: Boehringer Ingelheim P... http://t.co/QrEPkXXO
Lower Incidence Of Cardiovascular Events With Sitagliptin Compared To Sulphonylureas
medicalnewstoday.com — “The incidence of cardiovascular events in patients with type 2 diabetes treated with the DPP-4 inhibitor sitagliptin (Januvia) is significantly lower than in those treated with sulphonylureas, sho” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 6:05 pm By:
Lower Incidence Of Cardiovascular Events With Sitagliptin Compared To Sulphonylureas http://t.co/tuNUZzS7 #diabetes
Juvisync Available for Type 2 Diabetes and High Cholesterol - MPR
empr.com — “Merck announced that Juvisync, a fixed-dose combination product containing the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin and the HMG-CoA reductase inhibitor simvastatin is now available.” View full resource at empr.com
Most Recently Shared on October 26, 2011 at 1:57 pm By:
Juvisync Available for Type 2 #Diabetes and High #Cholesterol http://t.co/xM44w6TT
Medical News: EASD: Gliptin Tx Works Long-Term for Glycemic Control - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- Long-term treatment of type 2 diabetes with dipeptidyl peptidase-4 (DPP-4) inhibitors for two years appeared to maintain improvement in glycosylated hemoglobin A1c levels, researchers report” View full resource at medpagetoday.com
Most Recently Shared on September 20, 2011 at 4:25 pm By:
Roger D. Jones, PhD Health Executive, Health Social Media, PhD, and Doctor
Medical News: EASD: Gliptin Tx Works Long-Term for Glycemic Control - http://t.co/yClWGEGe from @medpagetoday #health #medicine
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment” View full resource at medpagetoday.com
Most Recently Shared on September 19, 2011 at 9:33 pm By:
Roger D. Jones, PhD Health Executive, Health Social Media, PhD, and Doctor
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - http://t.co/9D51Tv1U from @medpagetoday #health #medicine
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment” View full resource at medpagetoday.com
Most Recently Shared on September 17, 2011 at 6:02 pm By:
Yvo Sijpkens MD Doctor, Internist, Nephrologist, and Physician
Gliptins show a 30% relative risk reduction of suffering a major cardiac event. http://t.co/LwJ12Qxu @diabetes
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment” View full resource at medpagetoday.com
Most Recently Shared on September 16, 2011 at 9:17 pm By:
EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers (CME/CE) http://t.co/wUsmdYno
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment” View full resource at medpagetoday.com
Most Recently Shared on September 16, 2011 at 9:08 pm By:
EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers (CME/CE): LISBON (MedPage Today) -- While… http://t.co/wjbooIio
Eli Lilly and Company - Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
newsroom.lilly.com — “Eli Lilly and Company - Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes” View full resource at newsroom.lilly.com
Most Recently Shared on August 26, 2011 at 6:11 pm By:
Linagliptin only DPP-4 inhibitor approved at one dosage strength for adults with type 2 diabetes in Europe (Lilly) http://t.co/03eAQFp
Drugs for Diabetes: Part 5 DPP-4 Inhibitors - QualityPoint Technologies
qualitypointtech.net — “DPP-4 Inhibitors do not cause weight gain and, as a bonus, they have a very low incidence of hypoglycemia. Do they prevent heart disease, too? British Journal of Cardiology” View full resource at qualitypointtech.net
Most Recently Shared on July 21, 2011 at 1:00 pm By:
Drugs for Diabetes: Part 5 DPP-4 Inhibitors: DPP-4 Inhibitors do not cause weight gain and, as a bonus, they have ... http://bit.ly/qap0oT
Sitagliptin Shows Anti-inflammatory Activity In Diabetics - QualityPoint Technologies
qualitypointtech.net — “The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin exerts an anti-inflammatory effect in patients with type 2 diabetes at the cellular and molecular level, according to data reported at the 71st Scientific Sessions of the American Diabetes Association (ADA). Paresh Dandona, MD, chief of endocrinology at the State University of New York at Buffalo, and colleagues randomized 22 type 2 patients to 12 weeks' treatment with either 100 mg daily of sitagliptin or placebo...” View full resource at qualitypointtech.net
Most Recently Shared on July 10, 2011 at 11:45 pm By:
Sitagliptin Shows Anti-inflammatory Activity In Diabetics: The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin ... http://bit.ly/nIRPvO
Sitagliptin Shows Anti-inflammatory Activity In Diabetics
medicalnewstoday.com — “The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin exerts an anti-inflammatory effect in patients with type 2 diabetes at the cellular and molecular level, according to data reported at the 71” View full resource at medicalnewstoday.com
Most Recently Shared on July 10, 2011 at 11:14 pm By:
Endocrinology Wisdom OW Health
Sitagliptin Shows Anti-inflammatory Activity In Diabetics: The dipeptidyl peptidase (DPP)-4 inhibitor sitaglipti... http://bit.ly/pxyCNx
Sitagliptin Shows Anti-inflammatory Activity In Diabetics
medicalnewstoday.com — “The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin exerts an anti-inflammatory effect in patients with type 2 diabetes at the cellular and molecular level, according to data reported at the 71” View full resource at medicalnewstoday.com
Most Recently Shared on July 10, 2011 at 9:05 pm By:
Sitagliptin Shows Anti-inflammatory Activity In Diabetics http://mnt.to/3Y8p #diabetes
Linagliptin Helps Renally Impaired Diabetics - Renal and Urology News
renalandurologynews.com — “SAN DIEGO—Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, appears to be a good treatment option for patients with type 2 diabetes and severe renal impairment, researchers announced at the 71st Scientific Sessions of the American Diabetes Association.” View full resource at renalandurologynews.com
Most Recently Shared on July 6, 2011 at 12:09 pm By:
Renal Urology News Health News, Nephrology, Urology, and Medical Publisher
Linagliptin Helps Renally Impaired Diabetics: SAN DIEGO—Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, a... http://bit.ly/ncoPQL
Advertisement
